Fizelova Maria, Jauhiainen Raimo, Stančáková Alena, Kuusisto Johanna, Laakso Markku
Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland, Kuopio, Finland.
Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland.
PLoS One. 2016 Nov 16;11(11):e0166584. doi: 10.1371/journal.pone.0166584. eCollection 2016.
We investigated the association of the Finnish Diabetes Risk Score (FINDRISC) with insulin secretion, insulin sensitivity, and risk of type 2 diabetes, drug-treated hypertension, cardiovascular (CVD) events and total mortality in a follow-up study of the Metabolic Syndrome in Men (METSIM) cohort. The METSIM study includes 10,197 Finnish men, aged 45-73 years, and examined in 2005-2010. Of 8,749 non-diabetic participants of the METSIM study 693 developed incident type 2 diabetes, 225 started antihypertensive medication, 351 had a CVD event, and 392 died during a 8.2-year follow-up. The FINDRISC was significantly associated with decreases in insulin secretion and insulin sensitivity (P<0.0001), and with a 4.14-fold increased risk of incident type 2 diabetes, 2.43-fold increased risk of drug-treated hypertension, 1.61-fold increased risk of CVD, and 1.55-increased risk of total mortality (the FINDRISC ≥12 vs. < 12 points). In conclusion, the FINDRISC predicts impairment in insulin secretion and insulin sensitivity, the conversion to type 2 diabetes, drug-treated hypertension, CVD events and total mortality.
在男性代谢综合征(METSIM)队列的一项随访研究中,我们调查了芬兰糖尿病风险评分(FINDRISC)与胰岛素分泌、胰岛素敏感性、2型糖尿病风险、药物治疗的高血压、心血管(CVD)事件及全因死亡率之间的关联。METSIM研究纳入了10197名年龄在45 - 73岁之间的芬兰男性,并于2005 - 2010年进行了检查。在METSIM研究的8749名非糖尿病参与者中,693人发生了2型糖尿病,225人开始服用抗高血压药物,351人发生了CVD事件,392人在8.2年的随访期间死亡。FINDRISC与胰岛素分泌和胰岛素敏感性降低显著相关(P<0.0001),与2型糖尿病发病风险增加4.14倍、药物治疗的高血压风险增加2.43倍、CVD风险增加1.61倍以及全因死亡率风险增加1.55倍相关(FINDRISC≥12分与<12分相比)。总之,FINDRISC可预测胰岛素分泌和胰岛素敏感性受损、向2型糖尿病的转变、药物治疗的高血压、CVD事件及全因死亡率。
J Clin Endocrinol Metab. 2017-9-1
J Clin Endocrinol Metab. 2017-2-1
Diabetes Metab Res Rev. 2016-1
Diabetes Care. 2020-6
Cardiovasc Diabetol. 2025-1-18
Front Nutr. 2024-8-27
Rev Med Inst Mex Seguro Soc. 2023-1-2
Circ Res. 2020-6-5
Genome Biol. 2017-5-5
Kidney Int. 2015-3
Nat Rev Endocrinol. 2014-3-25
Diabetes Care. 2013-1
Eur Heart J. 2012-10
Diabet Med. 2012-1